



May 18, 2016

## Foundation Medicine Announces Presentations at ASCO

--Data Supports Comprehensive Genomic Profiling for Identifying Therapeutic Treatment Options and Determining Predictors of Therapeutic Response Across Broad Cancer Types--

CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)-- [Foundation Medicine, Inc.](#) (NASDAQ:FMI) today announced that the company and its collaborators will have two oral presentations, six poster discussions and nineteen posters presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 taking place June 3-7 in Chicago.

The schedule for **oral presentations** by Foundation Medicine and/or its collaborators is as follows:

**Date and Time:** Sunday, June 5, 2015 from 9:57 - 10:09 a.m. CT

**Title:** PD-L1 Expression, Cancer Genome Atlas (TCGA) Subtype and Mutational Load are Independent Predictors of Response to Atezolizumab (atezo) in Metastatic Urothelial Carcinoma (mUC; IMvigor210)

**Abstract Number:** 104

**Location:** Hall D1

**Session:** Immunotherapy: Now We're Getting Personal - Using Genomics and Biomarkers to Predict Response

**Session Type:** Clinical Science Symposium

**Presenter:** Jonathan E. Rosenberg, M.D., medical oncologist, Memorial Sloan Kettering Cancer Center

**Collaborator(s):** Memorial Sloan Kettering Cancer Center

**Date and Time:** Sunday, June 5, 2016 from 10:21 - 10:33 a.m. CT

**Title:** Hybrid Capture-Based Next-Generation Sequencing (HC NGS) in Melanoma to Identify Markers of Response to Anti-PD-1/PD-L1

**Abstract Number:** 105

**Location:** Hall D1

**Session:** Immunotherapy: Now We're Getting Personal - Using Genomics and Biomarkers to Predict Response

**Session Type:** Clinical Science Symposium

**Presenter:** Douglas Buckner Johnson, M.D., M.S.C.I., clinical director, melanoma, Vanderbilt-Ingram Cancer Center

**Collaborator(s):** Vanderbilt University

The schedule for **poster discussions** by Foundation Medicine and/or its collaborators is as follows:

**Date and Time:** Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT

**Discussion Time:** 3:00 - 4:15 p.m. CT

**Title:** Genomic Profiling to Distinguish Poorly Differentiated Neuroendocrine Carcinomas Arising in Different Sites

**Abstract Number:** 4020

**Poster Board Number:** 12

**Poster Display Location:** Hall A

**Discussion Location:** Hall D1

**Session:** Gastrointestinal (Noncolorectal) Cancer

**Presenter:** Emily K. Bergsland, M.D., endowed chair in medical oncology, University of California San Francisco

**Collaborator(s):** University of California San Francisco, Helen Diller Family Comprehensive Cancer Center

**Date and Time:** Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT

**Discussion Time:** 3:00 - 4:15 p.m. CT

**Title:** Total Mutation Burden (TMB) in Lung Cancer (LC) and Relationship with Response to PD-1/PD-L1 Targeted Therapies

**Abstract Number:** 9017

**Poster Board Number:** 340

**Poster Display Location:** Hall A

**Discussion Location:** E354b

**Session:** Lung Cancer - Non-Small Cell Metastatic

**Presenter:** David R. Spigel, M.D., chief scientific officer; director, lung cancer research program; principal investigator, Sarah Cannon Research Institute

**Collaborator(s):** Sarah Cannon Research Institute

**Date and Time:** Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT  
**Discussion Time:** 3:00 - 4:15 p.m. CT  
**Title:** Comprehensive Genomic Profiling of 298 Lung Cancers of Varying Histologies Harboring MET Exon 14 Alterations  
**Abstract Number:** 9021  
**Poster Board Number:** 344  
**Poster Display Location:** Hall A  
**Discussion Location:** E354b  
**Session:** Lung Cancer - Non-Small Cell Metastatic  
**Presenter:** Sai-Hong Ignatius Ou, M.D., Ph.D., medical oncologist, Chao Family Comprehensive Cancer Center, University of California Irvine  
**Collaborator(s):** Chao Family Comprehensive Cancer Center, University of California Irvine

**Date and Time:** Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CT  
**Discussion Time:** 4:45 - 6:00 p.m. CT  
**Title:** Comprehensive Genomic Sequencing (CGS) of 90 Patient Samples of Anaplastic Thyroid Cancer (ATC)  
**Abstract Number:** 6014  
**Poster Board Number:** 336  
**Poster Display Location:** Hall A  
**Discussion Location:** S406  
**Session:** Head and Neck Cancer  
**Presenter:** Saad A. Khan, M.D., medical oncologist, The University of Texas Southwestern Medical Center  
**Collaborator(s):** The University of Texas Southwestern Medical Center

**Date and Time:** Monday, June 6, 2016 from 8:00 - 11:30 a.m. CT  
**Discussion Time:** 1:15 - 2:30 p.m. CT  
**Title:** Evaluation of Microsatellite Instability (MSI) Status in 11,573 Diverse Solid Tumors using Comprehensive Genomic Profiling (CGP)  
**Abstract Number:** 1523  
**Poster Board Number:** 346  
**Poster Display Location:** Hall A  
**Discussion Location:** S404  
**Session:** Cancer Prevention, Hereditary Genetics and Epidemiology  
**Presenter:** Michael J. Hall, M.D., M.S., associate professor; director, gastrointestinal risk assessment, Fox Chase Cancer Center  
**Collaborator(s):** Fox Chase Cancer Center

**Date and Time:** Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT  
**Discussion Time:** 4:45 - 6:00 p.m. CT  
**Title:** DNA-Based Genomic Profiling for Classification of Tissue of Origin for Patients with Carcinoma of Unknown Primary Site  
**Abstract Number:** 11519  
**Poster Board Number:** 216  
**Poster Display Location:** Hall A  
**Discussion Location:** S406  
**Session:** Tumor Biology  
**Presenter:** Michael Goldberg, clinical data analyst II cancer genomics, Foundation Medicine

The schedule for **poster presentations** by Foundation Medicine and/or its collaborators is as follows:

**Date and Time:** Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT  
**Title:** Tumor Mutational Burden as a Potential Biomarker for PD-1/PD-L1 Therapy in Colorectal Cancer  
**Abstract Number:** 3587  
**Poster Board Number:** 284  
**Poster Display Location:** Hall A  
**Session:** Gastrointestinal (Colorectal) Cancers  
**Presenter:** Thomas J. George, M.D., F.A.C.P., medical director, gastrointestinal oncology, University of Florida  
**Collaborator(s):** University of Florida

**Date and Time:** Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT  
**Title:** Genomic Distinctions Between Colon and Rectal Cancer in Young Patients  
**Abstract Number:** 3574  
**Poster Board Number:** 271  
**Poster Display Location:** Hall A  
**Session:** Gastrointestinal (Colorectal) Cancer

**Presenter:** Joshua E. Meyer, M.D., assistant professor; residency/fellowship training director, department of radiation oncology, Fox Chase Cancer Center

**Collaborator(s):** Fox Chase Cancer Center

**Date and Time:** Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT

**Title:** *MDM2* Amplification (Amp) to Mediate Cabozantinib Resistance in Patients (Pts) with Advanced *RET*-Rearranged Lung Cancers

**Abstract Number:** 9068

**Poster Board Number:** 391

**Poster Display Location:** Hall A

**Session:** Lung Cancer - Non-Small cell Metastatic

**Presenter:** Romel Somwar, Ph.D., senior research scientist, pathology, Memorial Sloan Kettering Cancer Center

**Collaborator(s):** Memorial Sloan Kettering Cancer Center

**Date and Time:** Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT

**Title:** Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, Demographics, and Molecular Markers

**Abstract Number:** 9088

**Poster Board Number:** 411

**Poster Display Location:** Hall A

**Session:** Lung Cancer - Non-Small Cell Metastatic

**Presenter:** Vassiliki Papadimitrakopoulou, M.D., professor, department of thoracic/head and neck medical oncology, medical oncology, The University of Texas MD Anderson Cancer Center

**Collaborator(s):** The University of Texas MD Anderson Cancer Center

**Date and Time:** Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT

**Title:** Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer (CRC).

**Abstract Number:** 3589

**Poster Board Number:** 286

**Poster Display Location:** Hall A

**Session:** Gastrointestinal (Colorectal) Cancer

**Presenter:** Christopher Hanyoung Lieu, M.D., director, Colorectal Medical Oncology Program, deputy director, Cancer Clinical Trials Office, University of Colorado

**Collaborator(s):** University of Colorado

**Date and Time:** Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT

**Title:** Significant Systematic and CNS Activity of the *RET* Inhibitor Vandetanib Combined with mTOR inhibitor Everolimus in Patients with Advanced NSCLC with *RET* fusion

**Abstract Number:** 9069

**Poster Board Number:** 392

**Poster Display Location:** Hall A

**Session:** Lung Cancer - Non-Small Cell Metastatic

**Presenter:** Tina Cascone, M.D., Ph.D., hematology/oncology fellow, The University of Texas MD Anderson Cancer Center

**Collaborator(s):** The University of Texas MD Anderson Cancer Center

**Date and Time:** Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CT

**Title:** *TMPRSS-ERG* Fusion in Men with Prostate cancer(PCa) and Non-prostate Malignancies: Defining a role for Comprehensive Genomic Profiling (CGP) to guide Clinical Care

**Abstract Number:** 5037

**Poster Board Number:** 294

**Poster Display Location:** Hall A

**Session:** Genitourinary (Prostate) Cancer

**Presenter:** Primo Lara, M.D., associate director for translational research, University of California, Davis

**Collaborator(s):** University of California, Davis

**Date and Time:** Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CT

**Title:** Analysis of Tumor Mutational Burden (TMB) in > 51,000 Clinical Cancer Patients to identify Novel Non-Coding PMS2 Promoter Mutations Associated with increased TMB

**Abstract Number:** 9572

**Poster Board Number:** 177

**Poster Display Location:** Hall A

**Session:** Melanoma/Skin Cancers

**Presenter:** Zachary Rockow Chalmers, senior research associate, Foundation Medicine

**Date and Time:** Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CT

**Title:** Comprehensive Genomic Profiling of Neuroendocrine Carcinoma of the Prostate

**Abstract Number:** 5027

**Poster Board Number:** 284

**Poster Display Location:** Hall A

**Session:** Genitourinary (Prostate) cancer

**Presenter:** Philip J. Stephens, Ph.D., chief scientific officer, Foundation Medicine

**Date and Time:** Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CT

**Title:** Deep Sequencing of Metastatic Cutaneous Basal Cell and Squamous Cell Carcinomas to Reveal Distinctive Genomic Profiles and New Routes to Targeted Therapies

**Abstract Number:** 9522

**Poster Board Number:** 127

**Poster Display Location:** Hall A

**Session:** Melanoma/Skin Cancers

**Presenter:** Jeffrey S. Ross, M.D., medical director, Foundation Medicine

**Collaborator(s):** Albany College of Medicine

**Date and Time:** Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT

**Title:** The Genomics of Young Lung Cancer

**Abstract Number:** 9083

**Poster Board Number:** 406

**Poster Display Location:** Hall A

**Session:** Lung Cancer - Non-Small Cell Metastatic

**Presenter:** Barbara J. Gitlitz, M.D., associate professor of clinical medicine, University of Southern California Keck School of Medicine

**Collaborator(s):** University of Southern California Keck School of Medicine

**Date and Time:** Sunday, June 5, 2016 from 8:00 - 11:30 a.m. CT

**Title:** Biomarkers of Immune Checkpoint Inhibitor Response in Metastatic Breast Cancer: PD-L1 Protein Expression, *CD274* Gene Amplification, and Total Mutational Burden

**Abstract Number:** 3057

**Poster Board Number:** 379

**Poster Display Location:** Hall A

**Session:** Developmental Therapeutics and Translational Research

**Presenter:** Jeffrey S. Ross, M.D., medical director, Foundation Medicine

**Collaborator(s):** Albany College of Medicine

**Date and Time:** Monday, June 6, 2016 from 8:00 - 11:30 a.m. CT

**Title:** Distinct Age-Associated Genomic Profiles Identified in Acute Myeloid Leukemia (AML) Using FoundationOne Heme

**Abstract Number:** 7041

**Poster Board Number:** 33

**Poster Display Location:** Hall A

**Session:** Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allograft

**Presenter:** Katherine Tarlock, M.D., acting instructor, hematology-oncology, Seattle Children's Hospital

**Collaborator(s):** Fred Hutchinson Cancer Research Center

**Date and Time:** Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT

**Title:** Comparison of Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder to Reveal Key Differences in Mutational Profile and Load

**Abstract Number:** 4522

**Poster Board Number:** 145

**Poster Display Location:** Hall A

**Session:** Genitourinary (Nonprostate) Cancer

**Presenter:** Sumanta K. Pal, M.D., assistant clinical professor, department of medical oncology & therapeutics research, City of Hope

**Collaborator(s):** City of Hope

**Date and Time:** Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT

**Title:** Assessment of Tumor Mutation Burden from > 60,000 Clinical Cancer Patients Using Comprehensive Genomic Profiling

**Abstract Number:** 11558

**Poster Board Number:** 255

**Poster Display Location:** Hall A

**Session:** Tumor Biology

**Presenter:** Garrett Michael Frampton, Ph.D., associate director, bioinformatics, Foundation Medicine

**Date and Time:** Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT

**Title:** Immunotherapy (IO) Versus Targeted Therapy Triage in Advanced Endometrial Adenocarcinoma (aEA) by Coordinate Assessment Tumor Mutation Burden (TMB), Microsatellite Instability (MSI) Status, and Targetable Genomic Alterations (GA)

**Abstract Number:** 5591

**Poster Board Number:** 414

**Poster Display Location:** Hall A

**Session:** Gynecologic Cancer

**Presenter:** Alessandro Santin, M.D., professor of obstetrics, gynecology and reproductive sciences; clinical research program leader, gynecologic oncology program, Yale School of Medicine

**Collaborator(s):** Yale School of Medicine

**Date and Time:** Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT

**Title:** Comprehensive Genomic Profiling to Identify Clinically Relevant Genomic Alterations in Patients with Advanced Penile Cancers

**Abstract Number:** 4573

**Poster Board Number:** 195

**Poster Display Location:** Hall A

**Session:** Genitourinary (Nonprostate) Cancer

**Presenter:** Andre Poisl Fay, M.D.

**Collaborator(s):** Pontificia Universidade Católica do Rio Grande do Sul School of Medicine

**Date and Time:** Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT

**Title:** Decision Impact Analysis of Comprehensive Genomic Profiling (CGP) in Advanced Breast Cancer: A Prospective Study

**Abstract Number:** 11578

**Poster Board Number:** 275

**Poster Display Location:** Hall A

**Session:** Tumor Biology

**Presenter:** Raquel E. Reinbolt, M.D., assistant professor, internal medicine, college of medicine, The Ohio State University

**Collaborator(s):** The Ohio State University Medical Center James Comprehensive Cancer Center

**Date and Time:** Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT

**Title:** Investigating the Utility of Comprehensive Genomic Profiling for Patients with Newly Diagnosed Breast Cancer

**Abstract Number:** TPS11617

**Poster Board Number:** 312b

**Poster Display Location:** Hall A

**Session:** Tumor Biology

**Presenter:** Casey B. Williams, Pharm.D., BCOP, director, molecular and experimental medicine, Avera Health

**Collaborator(s):** Avera Cancer Institute

## **About Foundation Medicine**

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit <http://www.FoundationMedicine.com> or follow Foundation Medicine on Twitter (@FoundationATCG).

*Foundation Medicine<sup>®</sup> and FoundationOne<sup>®</sup> are registered trademarks, and FoundationACT<sup>™</sup> is a trademark of Foundation Medicine, Inc.*

## **Cautionary Note Regarding Forward-Looking Statements**

*This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of comprehensive genomic profiling, including FoundationOne, FoundationOne Heme and FoundationACT to identify genomic alterations, identify relevant therapies and improve patient outcomes; and the clinical relevance of comprehensive genomic profiling in cancer treatment and the development of targeted therapies. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and*

*adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that the results presented are found to lack scientific, medical or clinical utility or that subsequent research renders the results presented less useful or not useful in clinical practice; Foundation Medicine's services and molecular information platform will not be able to identify genomic alterations in the same manner as prior clinical data; and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.*

View source version on [businesswire.com](http://www.businesswire.com/news/home/20160518006547/en/): <http://www.businesswire.com/news/home/20160518006547/en/>

**Media Contact:**

Pure Communications, Inc.  
Dan Budwick, 973-271-6085  
[dan@purecommunicationsinc.com](mailto:dan@purecommunicationsinc.com)

or

**Investor Contact:**

Foundation Medicine  
Kimberly Brown, 617-418-2215  
[ir@foundationmedicine.com](mailto:ir@foundationmedicine.com)

Source: Foundation Medicine, Inc.

News Provided by Acquire Media